Idarucizumab for dabigatran reversal in daily clinical practice: A case series.

Background: Real-life experience with idarucizumab, which reverses the anticoagulant effect of dabigatran, is currently limited.

Objective: To evaluate efficacy and safety of the clinical use of idarucizumab after its availability in Slovenia.

Methods: We analysed consecutive cases treated with idarucizumab in Slovenia from January to October 2016.